• For Patients
    • ALIMTA® (pemetrexed for injection)
    • CYRAMZA® (ramucirumab)
    • ERBITUX® (cetuximab)
    • Portrazza® (necitumumab)
    • Verzenio Continuous Care™ Support Program
  • For Healthcare Providers
    • ALIMTA® (pemetrexed for injection)
    • CYRAMZA® (ramucirumab)
    • ERBITUX® (cetuximab)
    • Verzenio® (abemaciclib)
  • Contact Us

Sitemap

For Patients

  • ALIMTA® (pemetrexed for injection)
  • CYRAMZA® (ramucirumab)
  • ERBITUX® (cetuximab)
  • Portrazza® (necitumumab)
  • Verzenio Continuous Care™ Support Program

For Healthcare Providers

  • ALIMTA® (pemetrexed for injection)
  • CYRAMZA® (ramucirumab)
  • ERBITUX® (cetuximab)
  • Verzenio® (abemaciclib)

Contact Us

Prescribing Information for ALIMTA® (pemetrexed for injection)
Patient Prescribing Information for ALIMTA® (pemetrexed for injection)
Prescribing Information for CYRAMZA® (ramucirumab)
Prescribing Information for ERBITUX® (cetuximab), including BOXED WARNING
Prescribing Information for Portrazza® (necitumumab), including BOXED WARNING
Prescribing Information for Verzenio® (abemaciclib)
Patient Prescribing Information for Verzenio® (abemaciclib)
Terms of Use
Privacy Statement
Accessibility Statement
Sitemap

To speak to customer support:
Call 1-866-472-8663
Monday - Friday, 8am — 10pm ET

This site is intended for US residents ages 18 and over.

PP-OC-US-0176 02/2020 ©Lilly USA, LLC 2020. All rights reserved.

ALIMTA®, CYRAMZA®, ERBITUX®, Portrazza®, and Verzenio® are registered trademarks and Verzenio Continuous Care™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Terms of UsePrivacy StatementAccessibility StatementSitemap